FDA requests input on development of user fee program for biosimilar and interchangeable biological products

Posted by Food and Drug Administration--Press Releases on Monday May 9, 2011 Under News

The U.S. Food and Drug Administration is requesting input from stakeholders and the public relating to the development of a user fee program for biosimilar and interchangeable biological product (351(k)) applications.

Be Sociable, Share!

Comments are closed.